103 related articles for article (PubMed ID: 29479067)
1. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
Strati P; Ferrajoli A; Wierda WG; Jain N; Thompson PA; O'Brien SM; Rezvani K; Kantarjian HM; Burger JA; Hinojosa CO; Keating MJ; Estrov Z
Leukemia; 2018 Oct; 32(10):2278-2281. PubMed ID: 29479067
[No Abstract] [Full Text] [Related]
2. B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide.
Fürstenau M; Fink AM; Schilhabel A; Weiss J; Robrecht S; Eckert R; de la Serna J; Crespo M; Coscia M; Vitale C; Böttcher S; Weppner G; Ritgen M; Stilgenbauer S; Tausch E; Fischer K; Hallek M; Eichhorst B; Brüggemann M; Herling CD
Blood; 2021 Apr; 137(16):2267-2271. PubMed ID: 33512465
[No Abstract] [Full Text] [Related]
3. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.
Strati P; Keating MJ; Wierda WG; Badoux XC; Calin S; Reuben JM; O'Brien S; Kornblau SM; Kantarjian HM; Gao H; Ferrajoli A
Blood; 2013 Aug; 122(5):734-7. PubMed ID: 23801633
[TBL] [Abstract][Full Text] [Related]
4. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.
Strati P; Keating MJ; Burger JA; O'Brien SM; Wierda WG; Estrov Z; Zacharian G; Ferrajoli A
Haematologica; 2017 Dec; 102(12):e494-e496. PubMed ID: 28798068
[No Abstract] [Full Text] [Related]
5. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
[TBL] [Abstract][Full Text] [Related]
6. Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia.
Aue G; Sun C; Liu D; Park JH; Pittaluga S; Tian X; Lee E; Soto S; Valdez J; Maric I; Stetler-Stevenson M; Yuan C; Nakamura Y; Muranski P; Wiestner A
J Immunol; 2018 Oct; 201(7):1967-1974. PubMed ID: 30104242
[TBL] [Abstract][Full Text] [Related]
7. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia.
Moutouh-de Parseval LA; Weiss L; DeLap RJ; Knight RD; Zeldis JB
J Clin Oncol; 2007 Nov; 25(31):5047. PubMed ID: 17971612
[No Abstract] [Full Text] [Related]
8. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
Srinivasan S; Schiffer CA
Leuk Res; 2009 Apr; 33(4):561-4. PubMed ID: 18676017
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
Pettitt AR; Jackson R; Cicconi S; Polydoros F; Yap C; Dodd J; Bickerstaff M; Stackpoole M; Khan UT; Carruthers S; Oates M; Lin K; Coupland SE; Menon G; Kalakonda N; McCarthy H; Bloor A; Schuh A; Duncombe A; Dearden C; Fegan C; Kennedy B; Walewska R; Marshall S; Fox CP; Hillmen P
Haematologica; 2020 Dec; 105(12):2868-2871. PubMed ID: 33256390
[No Abstract] [Full Text] [Related]
10. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Itchaki G; Brown JR
Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?
Brown JR
Leuk Lymphoma; 2010 Aug; 51(8):1382-5. PubMed ID: 20624030
[TBL] [Abstract][Full Text] [Related]
12. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
Pinto A; Corazzelli G; De Filippi R
Cancer; 2012 Mar; 118(6):1738; author reply 1739. PubMed ID: 21766303
[No Abstract] [Full Text] [Related]
13. Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
Spina F; Rezzonico F; Farina L; Corradini P
Eur J Haematol; 2013 Apr; 90(4):340-4. PubMed ID: 23281656
[TBL] [Abstract][Full Text] [Related]
14. Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia.
Awais A; Tam CS; Kontoyiannis D; Ferrajoli A; Duvic M; Cortes J; Keating MJ
Clin Infect Dis; 2008 Apr; 46(7):e69-71. PubMed ID: 18444808
[TBL] [Abstract][Full Text] [Related]
15. The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).
Sekeres MA; Swern AS; Giagounidis A; List AF; Selleslag D; Mittelman M; Schlegelberger B; Göhring G; Li JS; Sugrue MM; Fenaux P
Blood Cancer J; 2018 Sep; 8(10):90. PubMed ID: 30291223
[No Abstract] [Full Text] [Related]
16. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Gentile M; Recchia AG; Vigna E; Mazzone C; Lucia E; Gigliotti V; Bossio S; Madeo A; Morabito L; Servillo P; Franzese S; Caruso N; De Stefano L; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Feb; 20(2):273-86. PubMed ID: 21214505
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.
Sher T; Miller KC; Lawrence D; Whitworth A; Hernandez-Ilizaliturri F; Czuczman MS; Miller A; Lawrence W; Bilgrami SA; Sood R; Wood MT; Block AW; Lee K; Chanan-Khan AA
Leuk Lymphoma; 2010 Jan; 51(1):85-8. PubMed ID: 20055660
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin A in the treatment of refractory B chronic lymphocytic leukemia (B-CLL).
Van Den Neste E; Maerevoet M; Martiat P; Ferrant A; Delannoy A; Michaux JL
Leukemia; 1995 Jun; 9(6):1102-3. PubMed ID: 7596177
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).
Chanan-Khan A; Egyed M; Robak T; Martinelli de Oliveira FA; Echeveste MA; Dolan S; Desjardins P; Blonski JZ; Mei J; Golany N; Zhang J; Gribben JG
Leukemia; 2017 May; 31(5):1240-1243. PubMed ID: 28140392
[No Abstract] [Full Text] [Related]
20. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.
Vitale C; Falchi L; Ten Hacken E; Gao H; Shaim H; Van Roosbroeck K; Calin G; O'Brien S; Faderl S; Wang X; Wierda WG; Rezvani K; Reuben JM; Burger JA; Keating MJ; Ferrajoli A
Clin Cancer Res; 2016 May; 22(10):2359-67. PubMed ID: 26733610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
